Cover Image

Drug‐drug interactions with candidate medications used for COVID‐19 treatment: An overview

Abstract Drug‐drug interaction (DDI) is a common clinical problem that has occurred as a result of the concomitant use of multiple drugs. DDI may occur in patients under treatment with medications used for coronavirus disease 2019 (COVID‐19; i.e., chloroquine, lopinavir/ritonavir, ribavirin, tociliz...

Full description

Saved in:
Bibliographic Details
Main Authors: Haleh Rezaee (Author), Fariba Pourkarim (Author), Samira Pourtaghi‐Anvarian (Author), Taher Entezari‐Maleki (Author), Touraj Asvadi‐Kermani (Author), Masoud Nouri‐Vaskeh (Author)
Format: Book
Published: Wiley, 2021-02-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Drug‐drug interaction (DDI) is a common clinical problem that has occurred as a result of the concomitant use of multiple drugs. DDI may occur in patients under treatment with medications used for coronavirus disease 2019 (COVID‐19; i.e., chloroquine, lopinavir/ritonavir, ribavirin, tocilizumab, and remdesivir) and increase the risk of serious adverse reactions such as QT‐prolongation, retinopathy, increased risk of infection, and hepatotoxicity. This review focuses on summarizing DDIs for candidate medications used for COVID‐19 in order to minimize the adverse reactions.
Item Description:2052-1707
10.1002/prp2.705

Similar Items